Valerie Kolbert, APRN
Psychiatric/Mental Health, Adult · Boca Raton, FLNPI 1902994510
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 442 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 17.6% — the pattern of someone who eats at a lot of different presentations.
Across 442 payments — averaging $33.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$3K
- AbbVie$2K
- Vanda Pharmaceuticals Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Otsuka America Pharmaceutical, Inc.$1K
- Neurocrine Biosciences, Inc.$1K
- plus $4K from 16 others
What the payments were for
- Food & beverage$14,686100%
- Education$550%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 68 | $2,595 |
| AbbVie | 93 | $2,457 |
| Vanda Pharmaceuticals Inc. | 61 | $1,703 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 50 | $1,673 |
| Otsuka America Pharmaceutical, Inc. | 24 | $1,285 |
| Neurocrine Biosciences, Inc. | 36 | $1,019 |
| Alkermes, Inc. | 30 | $1,001 |
| Johnson & Johnson | 13 | $878 |
| Axsome Therapeutics, Inc. | 11 | $593 |
| E.r. Squibb & Sons, L.L.C. | 3 | $241 |
| Sunovion Pharmaceuticals Inc. | 16 | $241 |
| Lundbeck LLC | 9 | $199 |
| Supernus Pharmaceuticals, Inc. | 4 | $189 |
| Bausch Health US, LLC | 8 | $145 |
| Avanir Pharmaceuticals, Inc. | 8 | $142 |
| Noven Pharmaceuticals, Inc. | 1 | $123 |
| Livanova USA, Inc. | 1 | $112 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $44 |
| Harmony Biosciences LLC | 1 | $44 |
| Acadia Pharmaceuticals Inc | 1 | $25 |
| Alfasigma USA, Inc. | 1 | $20 |
| Eisai Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Austedo XR$1,038
- CAPLYTA$947
- LYBALVI$872
- REXULTI$610
- VRAYLAR$580
- INGREZZA$506
- Fanapt$373
- Auvelity$335
- INVEGA SUSTENNA$286
- ABILIFY MAINTENA$250
- SPRAVATO$223
- COBENFY$154
- ABILIFY ASIMTUFII$125
- SUNOSI$124
- QELBREE$124
- AUSTEDO$123
- NUEDEXTA$123
- Xelstrym$123
- VNS Therapy Symmetry Model 8103 Generator$112
- VIVITROL$108
How this compares
Too few psychiatric/mental health, adult providers in Floridato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 22 | $168,689 |
| VraylarCariprazine Hcl | 36 | $81,867 |
| Aripiprazole | 24 | $8,361 |
| Quetiapine Fumarate | 224 | $6,588 |
| Lurasidone Hcl | 15 | $6,218 |
| Vilazodone Hcl | 30 | $3,817 |
| Bupropion XlBupropion Hcl | 100 | $3,154 |
| Lisdexamfetamine Dimesylate | 21 | $3,131 |
| Lamotrigine | 177 | $2,693 |
| Methylphenidate ErMethylphenidate Hcl | 16 | $2,345 |
| Memantine Hcl ErMemantine Hcl | 22 | $1,712 |
| Ramelteon | 16 | $1,665 |
| Mirtazapine | 54 | $1,411 |
| Atomoxetine Hcl | 18 | $1,035 |
| Trazodone Hcl | 72 | $1,006 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $1,019 | $168,68922 claims |
| AbbVieVraylar | $2,457 | $81,86736 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few psychiatric/mental health, adult providers in Floridaon file to place this against a meaningful peer group, so we don't.
Other psychiatric/mental health, adult in Boca Raton
- Judith WaltersCape Coral$6K
- Darlene McLaughlinSt Petersburg$2K
- Fara TrucchioTamarac$2K
- Gladys VargasDaytona Beach$2K
- Mary Stone-DuffyWest Palm Beach$1K
- Allison SlackParkland$1K
- Kathleen RoederNew Port Richey$276
- Sharon KriegerPalm Harbor$229
- Patricia LewisSt Augustine$138
- Jane DacriArcadia$114
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.